公开(公告)号：US20190032088A1

公开(公告)日：2019-01-31

申请号：US16073778

申请日：2017-02-24

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Veronique ZENNOU

IPC: C12N15/88 ,  A61K9/00 ,  C12N9/22 ,  C12N15/11 ,  A61K48/00 ,  A61K9/127

Abstract: The invention pertains to therapies that require gene editing, and more specifically to non-viral methods for in vivo delivery of endonuclease reagents to specific tissues or cells. According to the invention, the endonuclease reagents are encapsulated into micelle structures of 50 to 150 nm diameter for intravenous injection. The invention thus provides therapeutic composition including such micelles structures, by which endonuclease reagents can be released into cell under RNA form for their use in the treatment of gene related diseases.

公开(公告)号：US20190151478A1

公开(公告)日：2019-05-23

申请号：US16092417

申请日：2017-04-13

Applicant: CELLECTIS

Inventor： Julien VALTON ,  Veronique ZENNOU ,  Philippe DUCHATEAU ,  Laurent POIROT

IPC: A61K48/00 ,  A61P35/00 ,  A61P31/00

Abstract: The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering drug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific drug in case of occurrence of a serious adverse even. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.